Among patients with NSCLC harboring BRAF mutations, ~50% have the BRAF V600E mutation, which activates BRAF in its monomeric state and makes them sensitive to BRAF mutant-specific inhibitors. Here, BRAF is linked to non-small cell lung carcinoma.